Host Genetic Variants in the Pathogenesis of Hepatitis C

Fuente: Zenodo
Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rau, Monika, Baur, Katharina, Geier, Andreas
Format: Recurso digital
Veröffentlicht: Zenodo 2012
Schlagworte:
Online-Zugang:
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
_version_ 1866901461227536384
author Rau, Monika
Baur, Katharina
Geier, Andreas
author_facet Rau, Monika
Baur, Katharina
Geier, Andreas
contents (Uploaded by Plazi for the Bat Literature Project) Direct-acting antiviral drugs (DAAs) are currently replacing antiviral therapy for Hepatitis C infection. Treatment related side effects are even worse and the emergence of resistant viruses must be avoided because of the direct-antiviral action. Altogether it remains a challenge to take treatment decisions in a clinical setting with cost restrictions. Genetic host factors are hereby essential to implement an individualized treatment concept. In recent years results on different genetic variants have been published with a strong association with therapy response, fibrosis and treatment-related side effects. Polymorphisms of the IL28B gene were identified as accurate predictors for therapy response and spontaneous clearance of HCV infection and are already used for diagnostic decisions. For RBV-induced side effects, such as hemolytic anemia, associations to genetic variants of inosine triphosphatase (ITPA) were described and different SLC28 transporters for RBV-uptake have been successfully analyzed. Fibrosis progression has been associated with variants of Vitamin D receptor (VDR) and ABCB11 (bile salt export pump). Cirrhotic patients especially have a high treatment risk and low therapy response, so that personalized antiviral treatment is mandatory. This review focuses on different host genetic variants in the pathogenesis of Hepatitis C at the beginning of a new area of treatment.
format Recurso digital
id zenodo_https___doi_org_10_5281_zenodo_13530489
institution Zenodo
language
publishDate 2012
publisher Zenodo
record_format zenodo
spellingShingle Host Genetic Variants in the Pathogenesis of Hepatitis C
Rau, Monika
Baur, Katharina
Geier, Andreas
Hepatitis C infection
IL28B
SVR
fibrosis progression
host genetics
Biodiversity
Mammalia
Chiroptera
Chordata
Animalia
bats
bat
(Uploaded by Plazi for the Bat Literature Project) Direct-acting antiviral drugs (DAAs) are currently replacing antiviral therapy for Hepatitis C infection. Treatment related side effects are even worse and the emergence of resistant viruses must be avoided because of the direct-antiviral action. Altogether it remains a challenge to take treatment decisions in a clinical setting with cost restrictions. Genetic host factors are hereby essential to implement an individualized treatment concept. In recent years results on different genetic variants have been published with a strong association with therapy response, fibrosis and treatment-related side effects. Polymorphisms of the IL28B gene were identified as accurate predictors for therapy response and spontaneous clearance of HCV infection and are already used for diagnostic decisions. For RBV-induced side effects, such as hemolytic anemia, associations to genetic variants of inosine triphosphatase (ITPA) were described and different SLC28 transporters for RBV-uptake have been successfully analyzed. Fibrosis progression has been associated with variants of Vitamin D receptor (VDR) and ABCB11 (bile salt export pump). Cirrhotic patients especially have a high treatment risk and low therapy response, so that personalized antiviral treatment is mandatory. This review focuses on different host genetic variants in the pathogenesis of Hepatitis C at the beginning of a new area of treatment.
title Host Genetic Variants in the Pathogenesis of Hepatitis C
topic Hepatitis C infection
IL28B
SVR
fibrosis progression
host genetics
Biodiversity
Mammalia
Chiroptera
Chordata
Animalia
bats
bat
url https://doi.org/10.5281/zenodo.13530489